When the world went remote in 2020, it felt like a permanent reset. Kitchen tables became workstations, Zoom replaced conference rooms, and the once-sacred commute was traded for a short walk down the hall. Yet five years on, something unexpected is happening: a decisive push back to the office. Call it the Return-to-Office (RTO) reckoning, a phenomenon reshaping the modern workplace with all the nuance, tension, and compromise of a cultural tug-of-war.
Why Now?
The simple answer: normalization. What began as a public health necessity has evolved into a long-term recalibration. Employers are increasingly concerned with culture, collaboration, and mentorship; intangible elements they fear are diluted in fully remote environments.
This is why organizations across sectors are leaning into RTO policies. JPMorgan Chase made headlines by rolling out a five-days-a-week policy in early 2025, signaling that even knowledge-based industries see value in shared space. Meanwhile, in life sciences, where discovery and innovation often hinge on hands-on experimentation, companies like Moderna and Regeneron have stressed the need for teams to return to labs and offices at least part-time. For them, the case isn’t just cultural; it’s operational. Science simply can’t be pipetted from a home office.
The Case for Returning
Proponents of RTO highlight several advantages:
Collaboration & Innovation: Informal hallway conversations and in-person brainstorming sessions are credited with sparking new ideas. In biotech, that might mean a research associate suggesting an unexpected assay tweak or a regulatory expert catching an issue before submission.
Mentorship & Culture: Younger employees, particularly Gen Z, are gravitating toward the office for career visibility and real-time coaching. This is especially true in lab-heavy fields, where learning by watching seasoned scientists troubleshoot is invaluable.
Visible Productivity Gains: Some firms report tangible benefits: shorter project cycles, faster approvals, and stronger cross-functional alignment when key teams are co-located.
The Pushback
Yet, not everyone is eager to return. Employees in roles well-suited to remote work, such as data science, medical writing, or business development, question the broad need for in-office mandates. Some see it as a rollback of the trust and autonomy granted during the pandemic years.
Surveys suggest that up to 80% of employers have lost talent due to rigid RTO policies, and in competitive markets like biotech, where regulatory affairs specialists or clinical project managers are already scarce, losing talent can stall programs.
Mental health and work-life balance are also part of the resistance. Many professionals argue their lives were easier and more sustainable with flexible schedules. Interestingly, Baby Boomers—often thought of as traditionalists—are frequently the ones resisting most, while Gen Z shows greater willingness to be present for the sake of mentorship and growth.
A Hybrid Middle Ground
Between mandates and resistance lies the hybrid compromise. Roughly 85% of companies now allow some form of flexibility, with three days in the office the most common model. This hybrid approach is gaining particular traction in life sciences: lab teams remain on-site, while knowledge workers toggle between office and home. It’s a model designed to acknowledge both sides: operational needs and employee autonomy.
The Road Ahead
Five years post-COVID, the RTO debate isn’t about pandemic protocols anymore. It’s about who gets to define the identity of work. Employers are betting on culture, collaboration, and control. Employees are weighing freedom, well-being, and trust.
What’s certain is this: the outcome will shape not just office skylines or lab campuses, but the very future of how science—and business—get done.
